|
|
| (2 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT[[Foscarnet sodium]] |
| {{Foscarnet}}
| |
| {{CMG}}
| |
| | |
| ==Overview==
| |
| '''Foscarnet''' is the [[conjugate base]] of the [[chemical compound]] with the [[chemical formula|formula]] HO<sub>2</sub>CPO<sub>3</sub>H<sub>2</sub>. This [[phosphonic acid]] derivative is (marketed by [[AstraZeneca]] as foscarnet [[sodium]] under the trade name Foscavir®) is an [[antiviral]][[medication]] used to treat [[herpes viruses]], including [[cytomegalovirus]] (CMV) and [[herpes simplex]] viruses types 1 and 2 (HSV-1 and HSV-2). It is particularly used to treat [[CMV retinitis]].
| |
| ==Category==
| |
| Antiviral
| |
| | |
| ==US Brand Names==
| |
| FOSCAVIR<sup>®</sup>
| |
| | |
| ==FDA Package Insert==
| |
| | |
| ''' [[Foscarnet description|Description]]'''
| |
| '''| [[Foscarnet clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Foscarnet microbiology|Microbiology]]'''
| |
| '''| [[Foscarnet indications and usage|Indications and Usage]]'''
| |
| '''| [[Foscarnet contraindications|Contraindications]]'''
| |
| '''| [[Foscarnet warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Foscarnet adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Foscarnet drug interactions|Drug Interactions]]'''
| |
| '''| [[Foscarnet overdosage|Overdosage]]'''
| |
| '''| [[Foscarnet clinical studies|Clinical Studies]]'''
| |
| '''| [[Foscarnet dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Foscarnet how supplied|How Supplied]]'''
| |
| '''| [[Foscarnet labels and packages|Labels and Packages]]'''
| |
| | |
| ==Mechanism of Action==
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antibiotics]]
| |
| [[Category:Wikinfect]]
| |